Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion
